Neuraceq® Now Available in Mobile, AL

Life Molecular Imaging (LMI) and Jubilant Radiopharma have announced an expansion of their strategic partnership and licensing agreement to enhance the supply and distribution of Neuraceq®. This imaging agent, used for detecting beta-amyloid plaques in the brains of adults with cognitive impairment, will now be produced at Jubilant's manufacturing site in Mobile, Alabama. Neuraceq® serves as a critical tool in the assessment of patients for Alzheimer’s disease and other cognitive disorders.

Neuraceq® is an FDA-approved diagnostic agent that aids in evaluating beta-amyloid plaque density in the brain through Positron Emission Tomography (PET) imaging. It is especially valuable for patients being assessed for Alzheimer's Disease (AD) and other types of cognitive decline. The imaging results from Neuraceq® can significantly influence the diagnosis and treatment plans for these patients. A negative scan suggests a low likelihood of AD, while a positive scan indicates the presence of amyloid plaques, which may be associated with AD or other neurological conditions.

Colleen Ruby, the Chief Operating Officer for the Americas and APAC at Life Molecular Imaging, expressed enthusiasm over the expansion. She emphasized that this move highlights LMI's commitment to meeting the growing demand for beta-amyloid detection, which is crucial for confirming patient eligibility for new therapies. This expansion aims to support the increasing needs of customers in the region and to provide better access to Neuraceq® for patients, physicians, and pharmaceutical partners.

Renato Leite, President of Jubilant Radiopharmacies, shared Ruby’s sentiments, noting the importance of making Neuraceq® available in Mobile, Alabama. He pointed out that with over 6.2 million Americans living with Alzheimer's disease—a condition that profoundly affects memory, cognitive skills, and daily functioning—the availability of Neuraceq® offers new hope. This imaging agent is a valuable addition to the toolkit for diagnosing and evaluating patients with cognitive impairments.

Neuraceq® is indicated specifically for PET imaging to estimate β-amyloid neuritic plaque density in adults. It is important to note that while a negative scan can reduce the likelihood that cognitive impairment is due to AD, a positive scan does not conclusively diagnose AD or any other cognitive disorder. Neuraceq® should be used alongside other diagnostic tools.

Despite its usefulness, there are limitations to the use of Neuraceq®. It does not predict the development of dementia or other neurological conditions, nor is it effective for monitoring responses to therapies. Moreover, errors can occur in image interpretation, particularly in cases of severe brain atrophy or motion artifacts. These errors can impact the accuracy of the diagnosis.

The safety profile of Neuraceq® is based on data from 1,090 administrations to 872 subjects, with no serious adverse reactions reported. The most common side effects were minor injection site reactions such as erythema, irritation, and pain.

Both Life Molecular Imaging and Jubilant Radiopharma are committed to improving patient care through advanced imaging technologies. LMI focuses on developing groundbreaking PET radiopharmaceuticals for neurodegenerative and cardiovascular diseases. As an affiliate of Life Healthcare Group, LMI strives to lead in molecular imaging innovations. Jubilant Radiopharma, a division of Jubilant Pharma Ltd., is a key player in the radiopharmaceutical industry, providing development, manufacturing, and distribution services through a vast network of radiopharmacies.

This enhanced collaboration between LMI and Jubilant Radiopharma is poised to significantly improve the availability and distribution of Neuraceq®, thereby supporting better diagnostic and therapeutic outcomes for patients with cognitive impairments.